Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).

被引：1
|
作者：
Lee, Chung-Han
Shah, Amishi Yogesh
Hsieh, James J.
Rao, Arpit
Pinto, Alvaro
Bilen, Mehmet Asim
Cohn, Allen Lee
Di Simone, Christopher
Shaffer, David R.
Sarrio, Regina Girones
Ribe, Sara Gunnestad
Wu, Jane
Schmidt, Emmett, V
Perini, Rodolfo F.
Kubiak, Peter
Smith, Alan D.
Motzer, Robert J.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Texas Houston, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA
[5] Hosp Univ La Paz, Madrid, Spain
[6] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[7] Rocky Mt Canc Ctr, Denver, CO USA
[8] Arizona Oncol Associates, Tucson, AZ USA
[9] New York Oncol Hematol, Albany, NY USA
[10] Hosp Univ & Politecn La FE, Med Oncol Serv, Valencia, Spain
[11] Sorlandet Hosp Kristiansand, Kristiansand, Norway
[12] Eisai Inc, Woodcliff Lake, NJ USA
[13] Merck & Co Inc, Kenilworth, NJ USA
[14] Eisai Ltd, Hatfield, Herts, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5008
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma
    Eckel-Passow, Jeanette E.
    Ho, Thai H.
    Serie, Daniel J.
    Cheville, John C.
    Thompson, R. Houston
    Costello, Brian A.
    Dong, Haidong
    Kwon, Eugene D.
    Leibovich, Bradley C.
    Parker, Alexander S.
    CANCER MEDICINE, 2020, 9 (03): : 1152 - 1160
  • [22] Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
    Spirina, Liudmila
    Yurmazov, Zahar
    Usynin, Evgeny
    Kondakova, Irina
    Ladutko, Ekaterine
    Choynzonov, Evgeny
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2021, 43 (02) : 1072 - 1080
  • [23] Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
    Kammerer-Jacquet, Solene-Florence
    Deleuze, Antoine
    Saout, Judikael
    Mathieu, Romain
    Laguerre, Brigitte
    Verhoest, Gregory
    Dugay, Frederic
    Belaud-Rotureau, Marc-Antoine
    Bensalah, Karim
    Rioux-Leclercq, Nathalie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)
  • [24] Efficacy of cabozantinib (C) after PD-1/PD-L1 checkpoint inhibitors in metastatic renal cell carcinoma (mRCC): The Gustave Roussy experience
    Derosa, L.
    Rouche, J. A.
    Colomba, E.
    Baciarello, G.
    Routy, B.
    Albiges, L.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Tumor immune microenvironment determinants of response to lenvatinib and a PD-1 blockade in clear cell renal cell carcinoma
    Vuong, Lynda
    Kuo, Fengshen
    Jiang, Hui
    Mascareno, Eduardo A.
    Rappold, Phillip
    Sabio, Erich
    Weiss, Kate
    Cornish, Andrew
    Reese, Stephen
    Adlesic, Mojca
    Solit, David
    Frew, Ian
    Akin, Oguz
    Chen, Yingbei
    Li, Ming O.
    Chan, Timothy A.
    Hakimi, Ari A.
    CANCER RESEARCH, 2023, 83 (16)
  • [26] Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
    Montemagno, Christopher
    Hagege, Anais
    Borchiellini, Delphine
    Thamphya, Brice
    Rastoin, Olivia
    Ambrosetti, Damien
    Iovanna, Juan
    Rioux-Leclercq, Nathalie
    Porta, Camillio
    Negrier, Sylvie
    Ferrero, Jean-Marc
    Chamorey, Emmanuel
    Pages, Gilles
    Dufies, Maeva
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [27] Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
    Lee, C-H.
    Adachi, Y.
    Ikezawa, H.
    Li, S. D.
    Funahashi, Y.
    Minoshima, Y.
    Kubiak, P.
    Perini, R.
    Ren, M.
    Smith, A. D.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S564 - S565
  • [28] Phase 1/ 2 study of quavonlimab (Qmab) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor
    Deva, Sanjeev
    Mackiewicz, Jacek
    Dalle, Stephane
    Gogas, Helen
    Lugowska, Iwona
    Berrocal, Alfonso
    Menzies, Alexander M.
    Maio, Michele
    Nagrial, Adnan
    Eizmendi, Karmele Mujika
    Grob, Jean-Jacques
    Caglevic, Christian
    Lyle, Megan
    Martin-Liberal, Juan
    Altura, Rachel
    Ren, Yixin
    Khilnani, Anuradha
    Cyrus, Jobin
    Siddiqi, Shabana
    Lotem, Michal
    CANCER RESEARCH, 2022, 82 (12)
  • [29] A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
    Nunes-Xavier, Caroline E.
    Angulo, Javier C.
    Pulido, Rafael
    Lopez, Jose I.
    CURRENT UROLOGY REPORTS, 2019, 20 (01)
  • [30] A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
    Caroline E. Nunes-Xavier
    Javier C. Angulo
    Rafael Pulido
    José I. López
    Current Urology Reports, 2019, 20
12345